...
首页> 外文期刊>Archives of Physical Medicine and Rehabilitation >Comparison of high- and low-dose corticosteroid in subacromial injection for periarticular shoulder disorder: A randomized, triple-blind, placebo-controlled trial
【24h】

Comparison of high- and low-dose corticosteroid in subacromial injection for periarticular shoulder disorder: A randomized, triple-blind, placebo-controlled trial

机译:肩峰下注射高剂量和低剂量皮质类固醇激素治疗肩周关节疾病的比较:一项随机,三盲,安慰剂对照试验

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Objective: To determine whether subacromial injection with high-dose corticosteroid in patients with periarticular shoulder disorders is better than low-dose corticosteroid or placebo in improving pain, function, and active range of motion (AROM). Design: Multicenter, randomized, triple-blind, placebo-controlled trial. Setting: Primary (n=2) and university-affiliated (n=1) tertiary-care hospitals. Participants: Volunteers (N=79) with periarticular shoulder disorders with at least 1 month's duration of pain. Intervention: Participants were randomly assigned to receive ultrasound-guided subacromial injection with triamcinolone acetonide, 40 or 20mg, or placebo. After a single injection, participants were followed up for 8 weeks. Main Outcome Measures: Visual analog scale (VAS) of average shoulder pain level during the past 1 week, Shoulder Disability Questionnaire (SDQ), and angles of shoulder AROM (including flexion, abduction, external rotation, internal rotation) pre- and posttreatment at weeks 2, 4, and 8. Results: There were no significant differences among the 3 groups (triamcinolone acetonide, 40mg, group 1, n=27; triamcinolone acetonide, 20mg, group 2, n=25; placebo, group 3, n=27) in terms of demographic and clinical characteristics at baseline. (1) Within-group comparison: VAS score, SDQ score, and AROM for groups 1 and 2 significantly improved at weeks 2, 4, and 8 (P<.0167). However, there was no difference in VAS score, SDQ score, and AROM scores for group 3. (2) Between-group comparison: significant differences in VAS score, SDQ score, and abduction, external rotation, and internal rotation of AROM were shown between groups 1 and 2 and group 3 at weeks 2, 4, and 8 (P<.05). Conclusions: This was the first study to assess the efficacy of corticosteroid according to 2 different doses, which are the most widely used in subacromial injection for participants with periarticular shoulder disorders. This study showed no significant differences between the high- (triamcinolone acetonide, 40mg) and low-dose (20mg) corticosteroid groups, indicating preferred use of a low dose at the initial stage.
机译:目的:确定肩峰周围疾病患者肩峰下注射大剂量皮质类固醇在改善疼痛,功能和活动范围(AROM)方面是否优于小剂量皮质类固醇或安慰剂。设计:多中心,随机,三盲,安慰剂对照试验。地点:初级(n = 2)和大学附属(n = 1)三级护理医院。参加者:志愿者(N = 79)患有肩周关节疾病,疼痛持续时间至少1个月。干预:参与者被随机分配接受超声引导的肩峰下注射曲安奈德,40或20mg或安慰剂。单次注射后,对参与者进行了8周的随访。主要观察指标:治疗前和治疗后过去1周的平均肩痛水平的视觉模拟量表(VAS),肩部残疾问卷(SDQ)和肩部AROM的角度(包括屈曲,外展,外旋,内旋)第2、4和8周。结果:3组之间无显着差异(曲安奈德40mg,第1组,n = 27;曲安奈德20mg,第2组,n = 25;安慰剂,第3组,n = 25)。 = 27)基线时的人口统计学和临床​​特征。 (1)组内比较:第1、2组的VAS评分,SDQ评分和AROM在第2、4和8周显着改善(P <.0167)。但是,第3组的VAS分数,SDQ分数和AROM分数没有差异。(2)组间比较:显示VAS分数,SDQ分数,AROM的外展,外旋和内旋显着差异在第2周,第4周和第8周的第1组和第2组与第3组之间(P <.05)。结论:这是第一个根据2种不同剂量评估皮质类固醇功效的研究,这是肩峰下注射最广泛用于关节周围肩部疾病参与者的剂量。这项研究表明,高剂量(曲安奈德,40mg)和低剂量(20mg)的皮质类固醇组之间没有显着差异,表明在初始阶段优选使用小剂量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号